QuarterlyIQ Insights · MTD
Factors
The full factor breakdown (the numbers behind each rank). The overview page shows the same reads in short form; this is the depth.
Factor signals
Each factor is a parallel diagnostic with a plain-language read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 50% of the time over the next year (vs 57% for the rest of the cohort, n=3115).
The numbers
Over the trailing year it converted 1.05x of net income into operating cash flow. Historically, Health Care names rated fragile grew net income 40% of the time over the next year (vs 56% for the rest of the cohort, n=1703).
The numbers
Most sensitive to the broad stock market.
- the broad stock market: This stock moves with the broad market (high beta).β 1.08 · R² 0.31
Not enough signal to read sensitivity to real (inflation-adjusted) rates, the US dollar, long-term interest rates, Fed net liquidity (low R² over the window).
1 material management or governance event in the past 24 months, led by executive changes. Historically, Health Care names rated stable grew net income 56% of the time over the next year (vs 52% for the rest of the cohort, n=618).
The numbers
Not investment advice. As of 2026-06-09.
Earnings setup & market context
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
Why this setup
EPS estimate $10.94 → $10.79 (-1.4% / 30d). 2 raised, 7 cut, 10 covering analysts.
0 upgrades, 0 downgrades / 30d, 4 maintained. 54% of analysts rate Buy.
2 PT revisions / 30d. Avg target 20.9% above current price.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-09.